Xenetic Biosciences (XBIO)
NASDAQ:XBIO
Want to see XBIO full AI Analyst Report?
XBIO Stock Chart & Stats
$2.21
-$0.03(-0.75%)
At close: 4:00 PM EST
$2.21
-$0.03(-0.75%)
Day’s Range― - ―
52-Week Range$1.90 - $13.93
Previous CloseN/A
Volume4.73K
Average Volume (3M)1.70M
Market Cap
$7.74M
Enterprise Value-$1.88M
Total Cash (Recent Filing)$7.88M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.27
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding2,291,056
10 Day Avg. Volume5,053,508
30 Day Avg. Volume1,695,238
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.50
Price to Sales (P/S)1.24
P/FCF Ratio-1.61
Enterprise Value/Market Cap-0.24
Enterprise Value/Revenue-0.63
Enterprise Value/Gross Profit-0.63
Enterprise Value/Ebitda0.67
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.32
Revenue Forecast (FY)$3.00M
Bulls Say, Bears Say
Bulls Say
Debt-light Balance SheetNear-zero debt materially reduces refinancing and interest expense risk for an R&D-focused biotech. Low leverage preserves strategic optionality, lets management prioritize clinical programs over debt service, and lengthens flexibility in financing timing across the next several quarters.
Improving Revenue MomentumRe-accelerating top-line suggests improving commercial traction or successful program milestones. Durable revenue growth, even modest, reduces sole reliance on financing, supports incremental reinvestment in R&D, and provides a foundation for scaling operations over the coming months if trend persists.
Reduced Cash Burn TrendSequential improvement in cash burn indicates better cost management or more efficient program spending. Sustained reduction in cash outflows can extend runway, lower near-term dilution risk, and give management more time to advance assets before needing larger external capital raises.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow means the company must repeatedly access external capital to fund operations. This dependence creates dilution and execution risk, constrains strategic choices, and leaves the firm sensitive to funding market conditions over the medium term.
Large Recurrent Net LossesVery large negative margins consume shareholder equity and produce persistently negative returns. Until margins sustainably improve, the company cannot self-fund growth, limiting reinvestment capacity and increasing the likelihood of recurring financings that burden long-term capital structure and strategy.
Governance And Shareholder Engagement RiskRepeated adjournments signal weak shareholder engagement and governance friction. This can delay critical approvals, strategic transactions, or board actions, creating execution uncertainty and potentially hindering timely capital raises or partnerships over the coming months.
Xenetic Biosciences News
XBIO FAQ
What was Xenetic Biosciences’s price range in the past 12 months?
Xenetic Biosciences lowest stock price was $1.90 and its highest was $13.93 in the past 12 months.
What is Xenetic Biosciences’s market cap?
Xenetic Biosciences’s market cap is $7.74M.
When is Xenetic Biosciences’s upcoming earnings report date?
Xenetic Biosciences’s upcoming earnings report date is May 07, 2026 which is in 19 days.
How were Xenetic Biosciences’s earnings last quarter?
Xenetic Biosciences released its earnings results on Mar 25, 2026. The company reported -$0.253 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.253.
Is Xenetic Biosciences overvalued?
According to Wall Street analysts Xenetic Biosciences’s price is currently Overvalued.
Does Xenetic Biosciences pay dividends?
Xenetic Biosciences does not currently pay dividends.
What is Xenetic Biosciences’s EPS estimate?
Xenetic Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xenetic Biosciences have?
Xenetic Biosciences has 2,291,056 shares outstanding.
What happened to Xenetic Biosciences’s price movement after its last earnings report?
Xenetic Biosciences reported an EPS of -$0.253 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Xenetic Biosciences?
Currently, no hedge funds are holding shares in XBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xenetic Biosciences
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Technical Analysis
Ownership Overview
―
Insiders
0.74% Mutual Funds
0.72% Other Institutional Investors
98.24% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---